Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$2000 heads of lettuce. Hear they taste good.
All the best
Anyone notice bid side change, GBLL, after close?
Too funny.
GVRC 0.024
All the best
LTRX. Steady buys flowing in. Good Volume.
Looking good.
All the best
LTRX U/T. eom
MYCO. Sharkese for growing clients.
All the best
Added a couple more LTRX. eom
.4448 Vwap. eom
The NT10K buys them time. Glad to see it. News either today or tomorrow as per Frank so yes I'm holding. I expect this one to do well from these levels.
All the best
GBLL. NT10K filled
No significant events noted
http://www.sec.gov/cgi-bin/browse-edgar?company=Global+Links+Corp&CIK=&filenum=&State=&a....
All the best
GBLL. NT10K filled
No significant events noted
http://www.sec.gov/cgi-bin/browse-edgar?company=Global+Links+Corp&CIK=&filenum=&State=&a...
All the best
DNAP. Interesting read about IBM tie in.
Affy and IBM to Collaborate on Integrating Genomic, Patient Data
By J Karrow
NEW YORK, GenomeWeb News (March 30) - IBM and Affymetrix will collaborate to integrate genomic research data and patient information, the companies said today.
Affymetrix and IBM plan to combine open standards technologies, including Affymetrix's GeneChip technology and IBM's services in regulatory compliance, business integration, and systems integration, to create a system that will allow researchers to cross-reference genomic data with patient data.
In their collaboration, IBM and Affymetrix plan to work with research organizations and institutes, pharmaceutical companies, and other organizations.
The H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida will collaborate with the two companies to design clinical trials that take into account genetic research.
--------------------------------------------------------------------------------
Congrats on SKYL guys. Fabulous.
All the best
bottom feeding on some WWTR. eom
DNAP for 4s filed 3/29. Buying
http://www.nasdaq.com/asp/quotes_sec.asp?mode=&kind=&symbol=dnap&symbol=&symbol=&...
All the best
LTRX had news yesterday
LANTRONIX: Lantronix introduces new WiPort wireless 802.11 based embedded device server for machine-to machine device networking WiPort reduces the complexity of integrating networking capabilities, Cuts development costs, and accelerates time to mar
Irvine, CA, Mar 29, 2004 (M2 PRESSWIRE via COMTEX) -- Lantronix , Inc. (Nasdaq:
LTRX), today announced its new WiPort wireless embedded device server, a
complete network-enabling solution based on the IEEE 802.11b wireless standard.
WiPort allows original equipment manufacturers (OEMs) to easily add wireless
connectivity to their products by incorporating it onto a circuit board with
minimal engineering, thereby dramatically accelerating time to market.
In addition to eliminating the complexity of creating a network solution, the
WiPort functions independently of a PC, providing a fully integrated solution
that combines a processor, memory, 802.11b transceiver and dual high-speed
serial ports into a single compact module. Less than the size of a small
matchbook, the WiPort measures approximately 1 inch on a side, and includes a
wireless connection, proven operating system, an embedded Web and device server,
full TCP/IP protocol stack and WEP security.
"Lantronix led the industry with XPort, the world`s first integrated,
miniaturized device server. WiPort expands on XPort`s innovation by adding
802.11b wireless and further reinforces Lantronix`s leadership and range of
product offerings in device servers," said Marc Nussbaum, president and chief
executive officer for Lantronix. "Now OEM design engineers can rapidly add
wireless network connectivity to their products so that customers can remotely
access, monitor, and manage networked devices from any location using the
internet. With WiPort`s ease of installation, manufacturers in such segments as
security, industrial automation, heating and ventilation, medical devices, and
others, will be able to rapidly deploy wireless network-enabled products.
Our customers can quickly realize the benefits of establishing an Internet
presence for their products, all without the use of traditional Ethernet CAT-5
wiring," added Nussbaum.
"Many applications in the M2M world require the flexibility of a non-wired
solution. The WiPort addresses that need and should accelerate the adoption of
wireless connectivity in the device networking arena, ," said Glen Allmendinger,
president at Harbor Research, a strategic consulting and research firm.
Following up on its successful X-Port (wired) product, Lantronix is now leading
the way in device networking."
Using the widely adopted IEEE 802.11b protocol is a perfect match for the speed
and security needs of most devices. In addition, the WiPort can send email
alerts and supports numerous other network communication protocols, including
ARP, UDC, TCP, ICMP, Telnet, AutoIP, DHCP, HTTP and SNMP.
For OEMs who wish to customize the user interface by employing common and
familiar tools, the WiPort can serve applets to a Web browser, resulting in
interactive Web pages. This flexible customization of HTML Web pages and
configuration screens enables the WiPort to be easily tailored to fit each
customer`s unique requirements. The WiPort can be further customized to suit the
specific application challenge and can be used as the single, core embedded
processor and communications module in many devices.
Evaluation units of the WiPort are available now for qualified OEMs, with
general availability beginning in April, 2004. For more information about the
WiPort wireless embedded device server, visit the company`s web site at
www.lantronix.com or contact Lantronix at 800-526-8764
About Lantronix, Inc.
Lantronix, Inc. (NASDAQ: LTRX) is a provider of hardware and software solutions
ranging from systems that allow users to remotely manage network infrastructure
equipment to technologies that network-enable devices and appliances. Lantronix
was established in 1989, and its worldwide headquarters are in Irvine, Calif.
For more information, visit the company on the Internet at www.lantronix.com.
XPort and WiPort are trademarks of Lantronix. Lantronix is a registered
trademark of Lantronix, Inc. All other trademarks are properties of their
respective owners.
CONTACT: Nancy Mains, Lantronix Tel: +1 949 450 7244 e-mail:
nancymains@lantronix.com Nicholas J Parker, Director, Davies Adam Consulting
e-mail: nick@daviesadam.co.uk
M2 Communications Ltd disclaims all liability for information provided within M2
PressWIRE. Data supplied by named party/parties. Further information on M2
PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.
(C)1994-2004 M2 COMMUNICATIONS LTD
Thanks jawmoke. I must be loosing it and need to get away from the computer. If I'm not mistaken someone pointed that same thing out to me a couple of days ago. Short term memory loss or staring at the screen too much.
All the best
Thanks zeptepi. All the best. eom
jawmoke. MYCO. tomorrow the filing?
Thanks
All the best
DNAP. I swear they could name Jesus to their BOD and it still wouldn't move it. Thought todays PR would.
Of course thats what I get for thinking.
Holding for now.
All the best
Bought DNAP on news
(PR NEWSWIRE) DNAPrint(TM) genomics, Inc. Forms Joint Research Program With the
H. Lee Moffitt Cancer Center and Research Institute
DNAPrint(TM) genomics, Inc. Forms Joint Research Program With the H. Lee Moffitt
Cancer Center and Research Institute
SARASOTA, Fla., March 29 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: DNAP) (the "Company") of Sarasota, FL today announced
that it has formed a multi-faceted pharmacogenomics program with the H. Lee
Moffitt Cancer Center & Research Institute at the University of South Florida.
The program will aim to develop and implement new clinical tests for
predicting patient response to various cancer chemotherapies.
Moffitt physicians and scientists are teaming with DNAPrint to identify
genetic variants that underlie poor patient response to various
chemotherapies, and to implement new clinical tests at the Center combining
these variants with other biomarkers from gene-expression, proteomics and
epidemiological research. The aim of the tests will be to predict patient
chemotherapy response from the DNA before the commencement of the
chemotherapy, so that patients with a genetic proclivity for poor or non-
response can be spared from exposure to ineffective therapy. With the newly
signed agreement, both organizations have teamed to make an important stride
towards their goal of enabling a more personalized, safe and effective
modality of cancer treatment for our current generation of cancer patients.
The program is multi-faceted and presently defines study in several cancer
areas and clinical programs. Research will draw from several ongoing clinical
trials and epidemiology research projects underway at the Center. A primary
area of focus for the program is colorectal cancer, where DNAPrint will work
with primary investigator Dr. Timothy Yeatman, Moffitt's Associate Center
Director for Clinical Investigations. DNAPrint will implement its proprietary
ADMIXMAP genetic discovery platform to define gene sequences predictive for
response to two anti-cancer treatments, XELOX and XELIRI. Though representing
current FDA-approved therapies for metastatic colon cancer, approximately 50%
of patients fail to respond and given the poor prognosis associated with non-
response, there is a dire need for tools capable of predicting response
beforehand. The study design will aim to first discover and then evaluate
the predictive power of predictive Single Nucleotide Polymorphism (SNP)
markers in tandem with biomarkers from gene expression chip and proteomics
research currently under way at Moffitt. The first colon cancer study will
involve 100 patients. Other phases of this particular project will permit a
retrospective alignment of genetic risk and epidemiologic factors, and
prospective evaluation of chemotherapy response prediction in the setting of
GLP and FDA-approved clinical trial setting.
Over all of the program areas, the collaboration will combine Moffitt
oncologists, research scientists, mathematicians and software engineers with
DNAPrint computer scientists, molecular biologists and population geneticists,
and draw upon DNAPrint's pharmaceutical, clinical and regulatory expertise.
Moffitt will contribute gene expression and proteomics data resources
currently in development and DNAPrint will contribute its ADMIXMAP platform
and SNP analysis for mapping the genetic determinants of variable drug
response by harnessing the power of human population genetic structure. "We
have identified several clinical projects at the Moffitt that are of keen
commercial and social interest," said Dr. Hector J. Gomez, MD, PhD, Chairman
of the BOD and Chief Medical Officer of DNAPrint genomics, Inc. "Each of these
programs offers us the opportunity to advance cancer treatment in a
significant way," he said. Recent (November 2003) FDA guidance regarding
pharmacogenomics technologies promulgate that if markers are validated using
well understood markers in legitimate clinical environments, genetic tests
derived from those markers should be included in new drug applications.
Moffitt sees thousands of cancer patients each year, and ranks with M.D.
Anderson (Univ. Texas), Johns Hopkins (Baltimore, MD) and Fred Hutchinson
(Seattle, WA) as among the nation's busiest and most prestigious cancer
research centers. The center has established a domestic and international
network of collaborating physicians to build patient registries and implement
cutting-edge methods for reducing, treating or preventing the onset of cancer
diseases.
"Moffitt scientists and physicians were impressed with DNAPrint's ADMIXMAP
approach for using a population's structure as a fuel for mapping drug
response gene variants. We recognized its profound potential for contributing
to the enhancement of cancer treatment," said Moffitt's Dr. Timothy Yeatman.
Dr. Tony Frudakis, the scientific leader of DNAPrint and founder says, "By
virtue of its broad scope and scale, and given its clinical setting, this is
by far the most exciting research and product development opportunity yet for
our young company. Our goal is simple -- to present the FDA with what we can
do and to pave the way for our brand of personalized medicine as the gold
standard for drug development and use." He added, "The signing of this deal
illustrates Dr. Gomez's regulatory experience and leadership in the clinical
development and pharmaceutical product approval process. This is invaluable to
us as a company, as he brings a real world experience to our development
programs."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to
develop and sell genomic-based services. The Company introduced AncestrybyDNA
in the consumer market and DNA Witness in the forensic market in 2003.
DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the Nasdaq OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.CEO/President(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 03/29/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
+1-941-366-3400/
(DNAP)
CO: DNAPrint genomics, Inc.; H. Lee Moffitt Cancer Center and Research
Institute
ST: Florida
IN: MTC OTC
SU: JVN
*** end of story ***
GBLL bid u/t. eom
Added some LTRX. eom
Beggining to see MYCO like USTI. Fundementals are there but the company seems to not care about the share price or releasing news other than filings.
All the best
EZ. check your PM. eom
UNSP droping like a rock. eom
Jawmoke. BUGS. Spoke with them the other day. Still DD'ing this one. will let you know
All the best
BUGS. Anyone have opinions about this stock?
Thanks.
All the best
jawmoke, Shark is a good guy but waterlilies
Bloom anywhere from spring thru fall.
Still holding MYCO as well.
All the best
GBLL news tues or wed next week.
Spoke with Frank and he said update is coming but could not elaborate further.
All the best
I SENSE somethings up. Filing next week?
All the best
Just in for a minute but. GBLL news tues or wed next week.
Spoke with Frank and he said update is coming but could not elaborate further.
All the best
LTRX. Very nice buzz.
All the best
GFYF. Hard to belive Kahala or Lee Traupel would want to be associated with them given the treatment of shareholders today.
Feel kinda like that hocky player that got cold cocked last week.
Oh well. tommorow be another day.
BTW Art, thank you for the honest effort on the DD.
All the best
GFYF. Wow if that was an error. I'm beginning to like this on a long basis the more I read into this.
Of course I would like to realize some immediate gain also. LOL.
Kahala is big.
All the best
GFYF. This is who they have hooked their wagon to.
http://www.hoovers.com/kahala/--ID__107231--/free-co-factsheet.xhtml
All the best
Volume certainly has dried up. eom
OT. Held on to 200K in my retirement. Sold the other million at around .04. The day my sister died of an overdose of prescription drugs was the day I found out through the KY grants dept we had recieved the grant. Talk about irony.
I feel joined at the hip on that one.
All the best
Thanks Drugtester. will do. Actually I added quite a bit here yesterday.
All the best
Name change of the Quill?
true?
Anyone know why?
Thanks
All the best
GFYF going back up. eom